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Abstract
Background:  Familial Hypercholesterolemia (FH) is a common genetic disease and at the
molecular level most often due to mutations in the LDL receptor gene. In genetically
heterogeneous populations, major structural rearrangements account for about 5% of patients with
LDL receptor gene mutations.
Methods: In this study we tested the ability of two different quantitative PCR methods, i.e. Real-
Time PCR and Multiplex Ligation-Dependent Probe Amplification (MLPA), to detect deletions in
the LDL receptor gene. We also reassessed the contribution of major structural rearrangements
to the mutational spectrum of the LDL receptor gene in Denmark.
Results: With both methods it was possible to discriminate between one and two copies of the
LDL receptor gene exon 5, but the MLPA method was cheaper, and it was far more accurate and
precise than Real-Time PCR. In five of 318 patients with an FH phenotype, MLPA analysis revealed
five different deletions in the LDL receptor gene.
Conclusion: The MLPA method was accurate, precise and at the same time effective in screening
a large number of FH patients for large deletions in the LDL receptor gene.
Background
Familial Hypercholesterolemia (FH) is clinically charac-
terised by elevated concentrations of LDL-cholesterol in
plasma, tendon xanthomas and an increased risk of devel-
oping coronary artery disease inherited in an autosomal
dominant manner [1]. At the molecular level FH is most
commonly due to mutations in the LDL receptor gene, in
which more than 900 different mutations in the LDL
receptor gene have been reported worldwide [2,3].
Approximately 90 of them are various major structural
rearrangements such as deletions and insertions of sizes
ranging from 37 bp to 25 kb [2,3]. Major structural rear-
rangements account for approximately 5% of identified
mutations in the LDL receptor gene in genetically hetero-
geneous populations [1,4,5]. In Denmark four different
deletions in the LDL receptor gene have been described
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[6-8]. They were found in four of 97 patients tested [8].
Southern blotting, followed by hybridisation with LDLR
probes, has been used to screen for major structural rear-
rangements [6], but this method is labour-intensive and
requires large amounts of DNA. Alternatively long-range
PCR analysis has been used to amplify segments of the
LDL receptor gene up to approximately 20 kb in lengths
[9,10]. The major drawback of long-range PCR is that the
deletion or duplication has to be within the borders of the
primers of the amplified segment, because the allele con-
taining the deletion or duplication will otherwise not be
amplified, and the analysis result will falsely appear to be
homozygous wild-type (normal). With quantitative PCR
methods, it is possible to relate the number of allele cop-
ies to that of appropriate controls independently of the
extent of the deletion /insertion. Only small amounts of
DNA are required, and the methods are faster than South-
ern blotting analysis.
This study aimed at testing and comparing the abilities of
two quantitative PCR methods, i.e. Real-Time PCR and
Multiplex Ligation-dependent Probe Amplification
(MLPA) for detection of deletions in the LDL receptor
gene in a group of patients in whom deletions in the LDL
receptor gene had been demonstrated by Southern blot-
ting or long-range PCR analyses. If one of the methods
proved valid and effective, the study also aimed at re-esti-
mating the relative contribution of major structural rear-
rangements to the spectrum of LDL receptor gene
mutations in FH patients in Denmark.
Results
For testing and comparing Real-Time PCR and MLPA, sev-
enteen patients with a deletion of LDL receptor gene exon
5 were used as positive controls. The deletion of exon 5
was due either to a 9 kb deletion of exons 3–6 (14 patients
from one family) or to a 1 kb deletion only of exon 5
(three patients from two families) described by Rüdiger et
al and Jensen et al [6,8]. These mutations had been dem-
onstrated earlier by either Southern blotting or long-range
PCR analysis. Twelve individuals from the family with the
9 kb deletion that have been tested negative for the dele-
tion were used as negative controls.
Real-Time PCR
Real-Time PCR is a quantitative PCR method, which
quantifies the molecular concentration of DNA that can
serve as template for amplification [11]. The amplification
progress was measured by binding of SYBR Green to dou-
ble stranded DNA. SYBR Green is an intercalating dye, the
fluorescence of which is higher in the bound than in the
free-state [12]. The fluorescence signal is measured real-
time in the extension phase of the PCR reaction cycle, and
the measurement, proportional to the amount of double
stranded DNA, is plotted as an amplification curve against
cycle number. A threshold value of fluorescence in the
exponential part of the amplification curve is selected,
and for each sample the number of cycles needed for the
signal to reach the threshold is measured (threshold cycle
(CT)).
Quantification of the molecular concentration of tem-
plate DNA was performed with the standard curve
method [13]. Data analysis was performed with the iCy-
cler™ iQ Optical System Software Version 3.0a (BIO-
RAD), and the results were exported to Excel sheets for
storing and further processing. The copy number of exon
5 in the LDL receptor gene was divided by the copy
number of the reference gene (albumin). The ratio is 2:2
(i.e. 1) if both alleles of both genes are present, and the
ratio is 1:2 (i.e. 0.5) if one of the alleles of the target gene
is absent. In contrast, the ratio is 3:2 (i.e. 1.5) if one of the
alleles of the target gene has been duplicated.
Multiplex Ligation-dependent Probe Amplification 
(MLPA)
With the MLPA method developed by MRC-Holland [14],
relative quantification of up to 40 different DNA
sequences in one reaction is possible. Each MLPA probe
consists of two fluorescently labelled oligonucleotides
that can hybridise, adjacent to each other, to a target gene
sequence. When hybridised, the two oligonucleotides are
joined by a ligase, and the probe can then be amplified by
PCR. To each probe is attached a set of universal primers,
and one of the oligonucletides contains a stuffer sequence
of variable length that enables us to separate the single
fragments according to their length by gel electrophoresis
[14,15]. The area under peak for each fragment was meas-
ured with the GeneScan Analysis Software Version 3.1.2
and Genotyper Software Version 2.5 (Applied Biosys-
tems) and exported to Excel sheets for storing and for fur-
ther processing. The peak area was normalised by dividing
it by the combined area of all peaks in that lane. This nor-
malised peak area was then divided by average normal-
ised peak area from five normal control subjects. With this
method the results are given as allele copy numbers as
compared to normal controls, and a ratio of 1 is obtained
if both alleles are present, a ratio of 0.5 if one allele is
absent, and a ratio of 1.5 if one allele is duplicated.
A comparison of Real-Time PCR to MLPA for detection of
known deletions of LDL receptor gene exon 5 is given in
Table 1 and illustrated in Figure 1. With both Real-Time
PCR and MLPA analysis, it was possible to distinguish
between one and two copies of the LDL receptor gene
exon 5, but the coefficients of variation were larger for the
Real-Time PCR method than for the MLPA analysis. The
results of the MLPA analysis of 16 out of 18 exons in 14
patients with a 9 kb deletion of exons 3–6 are shown in
Figure 2 as wells as the results for 12 negative controls.BMC Medical Genetics 2005, 6:15 http://www.biomedcentral.com/1471-2350/6/15
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Table 1: Relative copy number of LDL receptor gene exon 5 measured with Real-Time PCR and MLPA
Method Sample population N Mean SD CV (%)
Real-Time PCR Normal 12 0.84 0.17 20
Deletion 17 0.44 0.097 22
MLPA Normal 12 1.03 0.02 2
Deletion 17 0.54 0.05 10
Mean relative allele copy number in 12 normal individuals and in 17 individuals with deletion of exon 5. SD: standard deviation. CV (%): coefficient 
of variation in percent.
Relative copy number of LDL receptor gene exon 5 Figure 1
Relative copy number of LDL receptor gene exon 5. Boxplots of relative copy number of LDL receptor gene exon 5 
measured with Real-Time PCR Analysis and MLPA analysis showing median; box: 25th -75th percentile; bars: largest and smallest 
values within 1.5 box lengths; circles: outliers.
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A cost-analysis and comparison of Real-Time PCR analysis
and MLPA analysis are given in Table 2. The cost analysis
included costs of reagents and laboratory technician time.
When 10 samples were analysed together, the MLPA
method was considerably cheaper as well as faster than
the Real-Time PCR method.
To expand our assessment of the contribution of major
structural rearrangements in the LDL receptor gene to the
spectrum of mutations causing FH [8], we further studied,
by MLPA analysis, 318 patients with an FH phenotype
referred for molecular genetic analysis to Aarhus Sygehus,
Aarhus University Hospital in the period January 1995 to
June 2004, in whom no mutations in the LDL receptor
gene had been detected by SSCP analysis and in whom the
apoB R3500Q mutation also had been excluded. Two-
hundred and seventy-six of these 318 patients have been
described previously [16].
A deletion of the LDL receptor gene was found in five
patients tested with the MLPA method. The five deletions
were a 9.3 kb deletion of the promoter and exon 1 [16], a
1 kb deletion of exon 5 [6], a 3 kb deletion of exons 7–8
[16,17], a 9.5 kb deletion of exons 9–14 [16] and 5 kb
deletion of exons 13–15 [17]. The graphical results of the
MLPA analysis are given in Figure 3. The detection of the
deletions was confirmed by long-range PCR analysis with
amplification of segments that MLPA analysis had sug-
gested might contain the deletion (data not shown).
Discussion
This study showed that the MLPA method unambiguously
discriminates between one and two copies of LDL recep-
tor gene exon 5. MPLA also enabled us to distinguish
clearly between deleted and non-deleted exons in patients
with a known 9 kb deletion of exons 3–6. Finally the
MLPA method proved efficient in screening of large num-
bers of patients for major structural rearrangements of
Mean relative copy numbers of exons in the LDL receptor gene Figure 2
Mean relative copy numbers of exons in the LDL receptor gene. Mean relative allele copy number ± SD of LDL recep-
tor gene exons 1–9, exons 11–12, exons 14–18, 5' (C3) and 3' (C12) flanking control fragments in 14 patients with a 9 kb dele-
tion of exons 3–6 measured with MLPA analysis compared to mean relative copy number in 12 normal controls.
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Table 2: Cost-analysis for detection of major structural 
rearrangements in the LDL receptor gene with quantitative PCR 
methods
Real-Time PCR MLPA
Price reagents (in euros) 1120 110
Time laboratory technician (hours) 56 14
Data are given for a batch of 10 samples tested in 16 exons in the LDL 
receptor gene with the Real-Time PCR method and with the MPLA 
method. Costs of data analysis and interpretation of results were the 
same for the two methods.BMC Medical Genetics 2005, 6:15 http://www.biomedcentral.com/1471-2350/6/15
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Graphical results of MLPA analysis Figure 3
Graphical results of MLPA analysis. Peak profiles of the MLPA analysis in one normal individual and in the five patients 
with the deletions described in the results section.
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almost the whole LDL receptor gene in one PCR reaction.
The protocol described by MRC Holland was followed,
and no further optimisation was necessary.
It was also possible to distinguish between carriers and
non-carriers of the exon 5 deletions with the Real-Time
PCR method. The coefficients of variations (CV) for meas-
urement of relative copy numbers with the Real-Time PCR
method were larger than with the MLPA method, how-
ever. The CV's found in this study are comparable to other
studies of measurements of relative allele copy numbers
with Real-Time PCR and the use of SYBR green fluores-
cence in other genes [18,19], but higher than coefficients
of variation reported with the use of TaqMan probes in
Real-Time PCR analysis [20,21]. This difference could be
due to multiplexing the PCR reactions when TaqMan
probes are used such that both test gene and reference
gene are amplified in the same reaction, which is not pos-
sible when SYBR Green fluorescence is used. It might have
been possible to reduce the coefficients of variation of the
Real-Time PCR analysis, with further optimisation or test
of more primer sets. However, with the present data the
intervals of mean ± 2SD's of relative allele copy numbers
in carriers and non-carriers are overlapping, and in a con-
siderably number of cases it was not possible to distin-
guish between one and two copies of exon 5 with the
same degree of certainty as with the MLPA method. If
screening of the entire LDL receptor gene was to be per-
formed, a segment representative of each exon had to be
amplified, and the need of optimisation would have been
extensive. That would also have been the case if TaqMan
probes were used and the PCR reactions were
multiplexed.
Thus, in our hands, the MLPA method was cheaper, and it
was more accurate and more precise than Real-Time PCR.
Previous work has not identified major structural rear-
rangements in the LDL receptor gene as a common cause
of FH in Denmark [8]. It has therefore been necessary to
employ a method for screening of the whole LDL receptor
gene for pathogenic variations. In the period January 1995
to June 2004, a mutation in the LDL receptor gene was
identified in 162 patients (data not shown) and large
deletions accounted for 3.1% (5 of 162) of these LDL
receptor gene mutation carriers, a finding similar to that
obtained in other genetically heterogeneous populations
[1,4,5]. In a study of Wang et al [22] eight different abnor-
mal patterns of MLPA analysis were found in 12 of 21
patients with a clinical diagnosis of FH in whom sequenc-
ing of the LDL receptor gene had not revealed any
mutations. In five patients with the same abnormal pat-
tern, this was confirmed as a deletion with another
method.
Conclusion
The MLPA method was accurate, precise and at the same
time effective in screening a large number of patients for
large deletions in the LDL receptor gene. Large deletions
accounted for the 3.1 % of LDL receptor mutation carriers
in the population studied.
Methods
DNA
Genomic DNA was extracted from EDTA stabilised blood
with the PUREGENE Genomic DNA Purification Kit
(Gentra Systems).
Real-Time PCR
A fragment of 116 bp located in exon 5 of the LDL recep-
tor gene was amplified with the following primer set: for-
ward exon 5 primer: 5'CCCTGCTTGTTTTTCTCTGG 3'
and reverse exon 5 primer: 5'TGCAGTTTCCATCAGAG-
CAC 3'. For relative quantification of number of alleles in
exon 5 of the LDL receptor gene, we used albumin as an
internal reference gene with the primers described by Lau-
rendeau et al [20]. PCR was carried out in reaction vol-
umes of 25 µL with 12.5 µL of iQ™ SYBR Green Supermix
(BIO-RAD), 300 nM of each primer and 4 ng of DNA. All
samples were analysed in triplicate, and each run included
separate standard curves for both primer pairs resulting
from the amplification of serially diluted (50 ng, 10 ng, 2
ng, 0.4 ng and 0.08 ng) control DNA. Thermal cycling was
performed on the iCycler™ iQ system (BIO-RAD) with a
first denaturation step of 90 s at 95°C, followed by 40
cycles at 94°C for 10 s, 61°C for 20 s and 72°C for 20 sec-
onds. PCR efficiencies in both reactions (exon 5 and albu-
min) were approximately 90%. Melting curve analysis was
performed to exclude amplification of non-specific
products.
Multiplex Ligation-dependent Probe Amplification 
(MLPA)
A kit for screening the LDL receptor gene for deletions or
duplications was obtained from MRC-Holland (SALSA
P062 LDLR exon deletion test kit). It contains probes for
16 out of 18 exons in the LDL receptor gene as well as two
probes for genes located just upstream and downstream of
the LDL receptor gene. It also contains 13 probes for other
human genes located on different chromosomes as con-
trols. MLPA was performed as described by Schouten et al
[14] and the manufacturer. Samples consisted of
approximately 100 ng of genomic DNA. The amplified
fragments were run on an ABI PRISM 377 DNA Sequencer
(Applied Biosystems).
Long-range PCR analysis
When the results of MLPA analysis suggested that a major
structural rearrangement was present in the LDL receptor
gene, the results were confirmed with long-range PCRPublish with BioMed Central    and   every 
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analysis [10] using the Expand 20 kbPLUSPCR System
(Roche). The sizes of deletions were estimated from the
difference in size of the amplified allele with the deletion
and the normal allele with long range PCR.
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